An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder.
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 17 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2009 190-week results reported by Eli Lilly.